Objectives: Coronavirus disease 2019 (COVID-19) is primarily known as a respiratory illness; however, a wide variety of symptoms and complications of the central nervous system (CNS), such as ischemic cerebrovascular accidents (CVA) have been reported. Hereby, we provide a systematic review and a meta-analysis of the literature, investigating the incidence of ischemic CVA and the mortality due to it in the setting of COVID-19.

Materials And Methods: Our search databases included Google Scholar, MEDLINE via PubMed, and Scopus. We searched the databases up to July 22, 2020. The primary outcome was the incidence of ischemic CVA in COVID-19 cases, while the secondary outcomes were the ratio of mortality in these cases. Standard meta-analysis methods used to measure the pooled incidence and mortality rates of ischemic CVA in COVID-19 cases.

Results: After excluding studies with reasons, only 20 articles were eligible to be included in our qualitative synthesis, and 17 studies were evaluated quantitatively in our meta-analysis. Included studies reported a pooled average incidence of 1.7% for ischemic CVA, ranging from 1.3% to 2.3%. Mortality in patients of ischemic CVA to all COVID-19 cases was 0.5%, ranging from 0.4% to 0.6%. The mortality rate of patients with CVA to those who suffered from COVID-19 infection and ischemic CVA simultaneously was 29.2% ranging from 21.6% to 38.2%. Overall, the heterogeneity of the studies was high.

Conclusions: Our analysis revealed a pooled incidence of 1.7% for ischemic CVA in the setting of COVID-19 infection, with a mortality rate of 29.2% amongst the COVID-19 patients who are suffering ischemic CVA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746086PMC
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2020.105552DOI Listing

Publication Analysis

Top Keywords

ischemic cva
32
covid-19 cases
12
cva covid-19
12
ischemic
10
cva
10
incidence mortality
8
ischemic cerebrovascular
8
cerebrovascular accidents
8
covid-19
8
systematic review
8

Similar Publications

Background: Edaravone is marketed in nine countries, although only Japan has approved edaravone for improvement of neurological symptom, disability of activities of daily living (ADL), and functional disability associated with acute stroke. This study aimed to elucidate the association of edaravone use with ADL using real-world data of older patients with atherothrombotic stroke.

Methods: This retrospective observational research using the Medical Data Vision database in Japan included patients aged 65 years and older who had acute ischemic stroke of the atherothrombotic subtype.

View Article and Find Full Text PDF

Background: Several studies have attempted to demonstrate the associations between body mass index (BMI) in early age and cardiovascular diseases (CVDs). However, their findings were inconsistent and inconclusive, indicating the need for further investigation.

Methods: We conducted a systematic review and meta-analysis of studies focusing on BMI in early age (age from 2 to 22) in relation to CVDs in adulthood, including coronary artery disease (CHD), ischemic and hemorrhagic stroke, myocardial infarction and heart failure.

View Article and Find Full Text PDF

Objectives: Physical activity (PA) provides protective effects against cardiovascular diseases, including ischaemic heart disease. However, recommending moderate to vigorous PA (MVPA) to patients with recent acute coronary syndrome (ACS) raises concerns owing to potential risk of recurrent ACS or fatal arrhythmias. This study investigated the association between longitudinal PA changes following an ACS diagnosis and subsequent cardiovascular outcomes, including non-fatal coronary events, non-fatal stroke and cardiovascular mortality.

View Article and Find Full Text PDF

Protective effects of wogonin in the treatment of central nervous system and degenerative diseases.

Brain Res Bull

January 2025

Department of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, 330006 Nanchang, Jiangxi, China. Electronic address:

Wogonin, an O-methylated flavonoid extracted from Scutellaria baicalensis, has demonstrated profound neuroprotective effects in a range of central nervous system (CNS) diseases. This review elucidates the pharmacological mechanisms underlying the protective effects of wogonin in CNS diseases, including ischemic stroke, hemorrhagic stroke, traumatic brain injury, epilepsy, anxiety, neurodegenerative diseases, and CNS infections. Wogonin modulates key signaling pathways, such as the MAPK, NF-κB, and ROS pathways, contributing to its anti-inflammatory, antioxidant, and antiapoptotic properties.

View Article and Find Full Text PDF

The immunology of stroke and dementia.

Immunity

January 2025

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:

Ischemic stroke and vascular cognitive impairment, caused by a sudden arterial occlusion or more subtle but protracted vascular insufficiency, respectively, are leading causes of morbidity and mortality worldwide with limited therapeutic options. Innate and adaptive immunity have long been implicated in neurovascular injury, but recent advances in methodology and new experimental approaches have shed new light on their contributions. A previously unappreciated dynamic interplay of brain-resident, meningeal, and systemic immune cells with the ischemic brain and its vasculature has emerged, and new insights into the frequent overlap between vascular and Alzheimer pathology have been provided.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!